Section Arrow
Quote
ATNM.NYSE-M
- Actinium Pharmaceuticals
(Financial Status)
Quotes are at least 15-min delayed:2026/07/05 16:30 EDT
Regular Hours
Last
 0.981
+0.0012 (+0.12%)
Day High 
0.99 
Prev. Close
0.9798 
1-M High
1.25 
Volume 
32.88K 
Bid
0.9809
Ask
1.03
Day Low
0.974 
Open
0.974 
1-M Low
0.94 
Market Cap 
30.74M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1 
20-SMA 1.02 
50-SMA 1.15 
52-W High 1.89 
52-W Low 0.94 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-0.76/-0.83
Enterprise Value
31.71M
Balance Sheet
Book Value Per Share
0.07
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
90.00K
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc0.1425+0.0277+24.13%-- 
PPCBPropanc Biopharma Inc.1.77+0.33+22.92%0PE
RXRXRecursion Pharmaceuticals3.8+0.13+3.54%-- 
IOVAIovance Biotherapeutics4.31+0.34+8.56%-- 
SLSSELLAS Life Sciences Group14.98+1.71+12.89%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.